Медицинский Совет

Расширенный поиск

Мелкие воздухоносные пути при бронхиальной астме – возможности терапии

Полный текст:


Согласно современным представлениям, бронхиальная астма (БА) определяется как хроническое воспалительное заболевание воздухоносных путей, в котором играют роль многие клетки и клеточные элементы. Хроническое воспаление ассоциировано с гиперреактивностью воздухоносных путей, что ведет к повторяющимся эпизодам хрипов, одышки, стеснения в груди, кашля (особенно по ночам и ранним утром). Эти эпизоды обычно ассоциированы с распространенной, но вариабельной обструкцией воздухоносных путей, которая часто обратима спонтанно или под влиянием терапии [1].

Об авторе

К. А. Зыков

Список литературы

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (updated 2013).

2. World Health Organization Asthma fact sheet. Date last accessed: September 2011. Date last updated: May 2011. mediacentre/factsheets/fs307/en/index.html

3. Masoli M., Fabian D., Holt S. et al. The global burden of asthma: executive summary of the GINA Dissemination Committee Report // Allergy. 2004. №59. Р. 469–478.

4. Colice G., Martin R.J., Israel E. et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone // J. Allergy Clin. Immunol.. 2013. Jul. №132(1). Р. 45–54.

5. Scichilone N., Spatafora M., Battaglia S. et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations // J. Asthma Allergy. 2013. №6. Р. 11-21.

6. Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient- reported asthma control in Europe in the past 5 years // Eur. Respir. Rev. 2012. №21. 123. Р. 66–74.

7. Soriano J.B., Rabe K.F., Vermeire P.A. Predictors of poor asthma control in European adults // J. Asthma. 2003. №40. Р. 803–813.

8. Piccinno A., Poli G., Monno R. et al. (2012) Extrafine Beclometasone Dipropionate and Formoterol in Single and Separate Inhalers // Clinic Pharmacol. Biopharm. 1:102. doi:10.4172/2167-065X.1000102

9. Barnes P.J. Similarities and differences in inflammatory mechanisms of asthma and COPD // Breathe. 2011. №7. Р. 229–238.

10. Laube B., Janssens H., De Jongh F. et al. What the pulmonary specialist should know about the new inhalation therapies // European Respiratory Journal. 2011. Vol. 37. №6. Р. 1308–1331.

11. Dolovich M., Ahrens R., Hessetal D. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology // Chest. 2005. Vol. 127. №1. Р. 335–371.

12. Sanchis J., Corrigan C., Levy M., Viejo J. Inhaler devices—from theory to practice // Respiratory Medicine. 2013. Vol. 107. №4. Р. 495–502.

13. Haldar P., Pavord I.D., Shaw D.E. et al. Cluster analysis and clinical asthma phenotypes // Am. J. Respir. Crit. Care Med. 2008. Aug. 1. №178(3). Р. 218–224.

14. Ambrosino N., Paggiaro P. The management of asthma and chronic obstructive pulmonary disease: current status and future perspectives // Expert Rev. Respir. Med. 2012. Feb. №6(1). Р. 117–127.

15. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist

16. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170(8):836-44

17. LazarusSC,BousheyHA,FahyJV,ChinchilliVM,Lemanske RF, Jr., Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285(20):2583-93

18. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337(20):1405-11

19. Takeda T, Oga T, Niimi A, et al. Relationship between small airway function and health status, dyspnea, and disease control in asthma. Respiration. 2010;80:120–126

20. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(Suppl 2):S447–S460.

21. Contoli M, Bousquet J, Fabbri LM, et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy. 2010;65(2):141–151

22. Virchow JC. [Asthma—a small airway disease: concepts and evidence]. Pneumologie 2009;63 Suppl 2:S96-101

23. Barnes PJ Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002, 19: 182-191

24. Mak JC, Nishikawa M, Barnes PJ Glucocorticosteroids increase β2- adrenergic receptor transcription in human lung. Am J Physiol, 1995, 268: L41-L46.

25. Tanaka H, Hashimoto M, Fujii M Reduction of Eosinophils in Small Airways by Inhaled Steroids is Insufficient in Patients with Adult Asthma. Allergology International. 2006;55:305-309

26. Hauber HP, Gotfried M, Newman K et al. Effect of HFA- flunisolide on peripheral lung inflammation in asthma. J. Allergy Clin. Immunol. 2003;112:58-63

27. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, et al. (1999) Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 104: 1215-22.

28. Rigamonti E, Kottakis I, Pelc M, Grzelewska Rzymowska I, Feschenko Y (2006) Comparison of a new extrafine beclometasone dipropionate HFA 134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma. Eur Respir J 28: 206-207.

29. Bousquet J, Poli G, Acerbi D, Monno R, Ramael S, et al. (2009) Systemic exposure and implications for lung deposition with an extrafine Hudrofluroalkane beclometasone dipropionate/formoterol fixed combination. Clin Pharmacokinet 48: 347-358.

30. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62(10):1182–1188

31. Papi A, Paggiaro PL, Nicolini G et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007 Apr;29(4):682-9

Просмотров: 74

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)